Results 131 to 140 of about 69,773 (297)
Summary Background and objectives Pruritus is a frequent cutaneous immune‐related adverse event (irAE) associated with immune checkpoint inhibitors (ICI), impacting patients' quality of life. This study investigates the incidence, severity and management of pruritus in melanoma patients treated with ICI.
Andrea Roggo +6 more
wiley +1 more source
Targeting the microbiota‐miRNA‐protease axis: A new therapeutic avenue in melanoma
Modulation of extracellular matrix (ECM) turnover is central to melanoma progression and metastasis, driven largely by ECM proteases. This review highlights the epigenetic regulation of ECM proteases by microRNAs and their roles in melanoma growth, invasion, and immune modulation.
Elias N. Katsoulieris +2 more
wiley +1 more source
This study assessed the 2022 WHO classification for predicting RAIR disease in thyroid carcinomas, comparing it to older classifications. In a retrospective study of 253 cases, we found the 2022 classification more effective, especially by identifying high‐grade carcinomas and tumour necrosis as critical predictive factors.
Elise André +10 more
wiley +1 more source
Welfare- and trade-based indicators of national distortions to agricultural incentives [PDF]
Distorted incentives, agricultural and trade policy reforms, national agricultural development, Agricultural and Food Policy, International Relations/Trade, F13, F14, Q17, Q18,
Anderson, Kym +2 more
core +1 more source
Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas
When questioning the effectiveness of adjuvant immunotherapy for acral melanomas, we found no clinical benefit to the adjuvant proposal, despite the maintenance of adverse effects. Abstract Background Solar factors play no role in the development of acral melanoma (AM). AM is characterized by low cumulative solar damage (low CSD).
Damien Sanogo +13 more
wiley +1 more source
International Dermoscopy Society consensus recommendations for the management of lentigo maligna
Lentigo maligna (LM) poses diagnostic and therapeutic challenges amid rising incidence and limited high‐quality evidence. This international expert consensus provides pragmatic, evidence‐based and expertise‐informed guidance on LM diagnosis and management.
Ana‐Maria Forsea +52 more
wiley +1 more source

